Email: This email address is being protected from spambots. You need JavaScript enabled to view it. Phone:617-632-3676 Tim graduated from the University of Rhode Island in 2017 with Bachelor of Science in Public Health. Immediately after graduation he immersed himself into the healthcare field as EMT in the Boston area and then transitioned over to an administrative role at Dana Farber Cancer Institute in the hematologic malignancies department. He’s looking forward to using his administrative and clinical skills on the Waldenstrom's Macroglobulinemia team.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it. Phone:617-632-3823 Prior to joining the Bing Center, Dr. Sarosiek completed her Internal Medicine residency, as well as her Amyloidosis and Hematology/Oncology Fellowship at Boston University Medical Center. After completing her training she remained as a faculty member at Boston University for 4 years. During that time she worked as a hematologist treating patients with benign and malignant hematologic issues, such as monoclonal gammopathy of undetermined significance (MGUS), lymphoma, WM, and multiple myeloma. She focused the majority of her research efforts on plasma cell disorders, including MGUS, multiple myeloma and amyloidosis. She also actively participated in the care of patients at the Boston University Amyloidosis Center and has published many original research articles in that field. She is looking forward to using the expertise she gained at that center to improve the care of patients with WM and AL amyloidosis. In the Bing Center Dr. Sarosiek works with Dr. Castillo in the clinic to see patients and help care for the constantly increasing number of Waldenstrom patients at our center. She is also actively involved in clinical research with her research efforts focused on the use of immunotherapies and antibody treatments in WM, as well as developing therapies and caring for those patients who have both WM and AL amyloidosis.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it. Phone:617-632-3685 (Monday-Friday 8a-5p; for non-urgent items only. For medical emergencies, please have Dr. Castillo paged through the pager operator at 617-632-3352) I am the nurse practitioner (NP) at the Bing Center for Waldenstrom Macroglobulinemia (BCWM). I joined the team in September 2019, and I am very proud to work with this driven and caring group of colleagues (and patients). As the BCWM team NP, I personally see patients in the BCWM clinic and I work closely with our physician team in delivering care to our patient population. I enjoy working with individuals across the spectrum of their disease (spanning from watchful waiting to active treatment), and offering my skills in listening, health assessment, patient education, problem solving, and symptom management. I am a sub-investigator on BCWM-led clinical trials which explore use of investigational treatment regimens for WM. I contribute to the overall conduct of these clinical trials, especially in regards to direct care management and evaluation of trial participants. I have been a sub-investigator on studies exploring treatments including zanubrutinib (subsequently FDA approved for WM), venetoclax (subsequently recommended for WM use per NCCN guidelines), pirtobrutinib, CLR-131, loncastuximab tesirine, novel combination therapies, ulocuplumab, umbralisib, mavorixafor, and more to come. Outside of clinical trials, I am also involved in the care of patients treated with standard of care regimens such as BTK inhibitors, proteasome inhibitors, monoclonal antibodies, BCL2 inhibitors, and chemotherapies. I have co-authored peer-reviewed publications, and contributed to work presented by fellow BCWM team colleagues and collaborators at meetings…

  Phone: 617-582-8235Email: This email address is being protected from spambots. You need JavaScript enabled to view it. Amanda joined the Bing Center in September, 2016 and assists Dr. Lian Xu in processing samples of peripheral-blood and bone marrow of treated and untreated patients for the serum and gDNA banks. Her Bachelor of Science in Biology with a minor in Business, was received from Suffolk University. Her previous work in research featured reconstructing mammalian dietary ecology using dental microwear and craniodental morphology at the Department of Biology of Suffolk University. Amanda has received Young Investigator Awards from the 10th International Workshop on WM (IWWM-10) and the 17th International Myeloma Workshop (IMW-17).

Email: This email address is being protected from spambots. You need JavaScript enabled to view it. Zachary joined the Bing Center in 2003 as clinical research coordinator and was so taken with medical research and the study of WM that despite his background in Mathematics and Physics, he retrained in Biology and ultimately received Ph.D. in Pathology from Boston University in 2015. He is now Instructor of Medicine at Harvard Medical School and the Bliss Family Investigator at the Bing Center for WM where he oversees the genomic and bioinformatic efforts for the group. With over 125 peer reviewed articles, his achievements include the initial identification and characterization of the recurrent MYD88, CXCR4, and ARID1A mutations in WM. He also published the initial genomic and transcriptional characterization of both MYD88 mutated and MYD88 wildtype WM. He contributed to the efforts characterizing primary and acquired resistance to BTK inhibitor therapy, WM clonal evolution, and familial Waldenstrom’s Macroglobulinemia. He has given over 60 scientific talks including at the American Society of Hematology, The American Society of Clinical Oncology, International Conference on Malignant Lymphoma, and the International Workshops on both Waldenstrom’s and Multiple Myeloma. He is very committed to patient education and has spoken in over 30 patient educational events. Dr. Hunter is the recipient of the Robert A. Kyle award and the American Society of Hematology Scholar Award. His current research includes the use of large multi-omic datasets and artificial intelligence models to characterize the evolution and distinct subtypes of WM, alternative splicing and RNA regulation, and WM Familial predisposition.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it. In 2005, Xia Liu began work as a Senior Research Technician in the Department of Medical Oncology, Dana Farber Cancer Institute, Boston. Many project focuses involve suppressor cells and their function against autoimmune diseases. Xia joined the Bing Center for Waldenstrom’s Research, DFCI in July 2007. Now she is working on the pathogenesis of Waldenstrom’s macroglobulinemia. Mrs. Liu received her degrees in Medical Science in Shanghai, China. After graduation, she worked at the Shanghai Railway hospital as a physician and lecturer. In 1999, MRs. Liu focused her work in research at Ohio State University, later to aspire to Harvard University as a research assistant. She has been well trained in molecular and cellular biology, histology, immuno-histochemistry, and signal transductions. As she continues to work with Waldenstrom’s macroglobulinemia, her concentrations are focused on a pathogenesis level.

Phone: 617-632-2681Email: This email address is being protected from spambots. You need JavaScript enabled to view it. Dr. Steven Treon is the Director of the Bing Center for Waldenström's Macroglobulinemia and an Attending Physician for the Department of Medical Oncology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston, Massachusetts. He is also a Professor of Medicine at Harvard Medical School in Boston, and is the Chair of the Waldenström's Macroglobulinemia Clinical Trials Group. Dr. Treon received a medical degree with honors from the Boston University School of Medicine, and a master’s degree in biochemistry and a doctorate of philosophy in tumor immunology from the graduate school at Boston University Medical Center. Dr Treon completed an internship and residency in internal medicine at Boston University Medical Center. He also completed a clinical fellowship in hematology and oncology at the Massachusetts General Hospital and a research fellowship at the Dana-Farber Cancer Institute and Harvard Medical School. He received certification from the American Board of Internal Medicine (ABIM) in Internal Medicine and Medical Oncology, and continues to maintain his ABIM certification in Medical Oncology. Dr. Treon’s research interests are focused on understanding the genetic basis and pathogenesis of Waldenström’s Macroglobulinemia (WM), and the development of targeted therapeutics for this malignancy. Using whole genome sequencing, the Treon laboratory discovered the highly prevalent MYD88 L265P and CXCR4 WHIM mutations in WM, permitting the development of diagnostic molecular testing and targeted treatments for WM. Signaling work performed in the Treon laboratory established the critical role of Bruton’s Tyrosine Kinase (BTK) as a key mediator of MYD88…

Phone: 617-582-7306Email: This email address is being protected from spambots. You need JavaScript enabled to view it. Phil first joined the Bing Center for WM in late 2003 as a volunteer. He developed a software application that automated the manual data collection processes to support our various research projects, resulting in a 90% reduction of the data collection time required for these projects. He also maintained the Bing Center websites to support previous and upcoming conferences and research efforts. Since joining the staff in 2009, he continues to maintain existing websites, develop new websites and software applications, as well as provide specialized technical support for the research staff where needed. He also provides project management for our bi-annual Patient & Physician Summits and WM Workshops in the areas of graphics design, program books & other printed materials, conference A/V and keeping the presentations running smoothly. Phil has over 30 years of experience in the high tech industry as a software developer and project manager, particularly in the telecommunications area. He has a BS in Systems Engineering from Boston University, and holds a patent for the design of a digital teleconferencing system. Phil, his wife Kathy and their 2 birds (Baby & Carl) currently reside in Haverhill, MA, and enjoy visiting with their three other “kids”, Steve, Marissa, and Matt.

Nick joined our group in November, 2013, having recently graduated from Boston University with a degree in Neuroscience. At BU, he spent a year in an experimental psychology lab programming operant chambers while studying auditory memory in rats. Nick will act as an intern in the Bing Center, where he will be collecting and processing blood samples for storage in our serum bank, and assisting the team in various other research projects. Nick resides in Roslindale, where he spends his time playing basketball, watching movies, and reading the latest medical research journals.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it. Phone: 617-632-5598 Kirsten joined the Bing Center for Waldenstrom’s macroglobulinemia, Dana Farber Cancer Institute in March 2013. She received her Bachelor of Arts in Pyschology and minors in Biology and Statistical Methods from Boston University in 2007, and completed her Masters of Public Health degree with concentrations in Epidemiology and Social and Behavioral Science at Boston University School of Public Health in 2009. Prior to working with the Bing center, she worked in clinical trials with the Lank Center for Genitourinary Oncology at DFCI. Kirsten is currently working on Bing Center related clinical trials opened by Dr. Treon and Dr. Castillo.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it. Dr. Castillo was born in Peru, received his medical degree at the Universidad Autonoma Metropolitana in Mexico City, and completed his Internal Medicine, and Hematology & Oncology training at the University of Massachusetts and Brown University, respectively. Dr. Castillo is an Associate Professor at Harvard Medical School, Senior Physician at the Dana-Farber Cancer Institute, and Clinical Director of the Bing Center for Waldenström Macroglobulinemia. Dr. Castillo is the principal investigator in innovative clinical trials evaluating highly effective non-chemotherapeutic approaches for patients with Waldenström macroglobulinemia. Research grants were obtained from Abbvie and Pharmacyclics to study the combination of ibrutinib and venetoclax in previously untreated Waldenström Macroglobulinemia (DFCI 19-651), AstraZeneca to investigate the combination of acalabrutinib and rituximab in patients with anti-MAG neuropathy (DFCI 21-439), and LOXO to investigate the combination of pirtobrutinib and venetoclax in patients with previously treated Waldenström Macroglobulinemia (DFCI 22-611). Funding from the Kaplan Family and the International Waldenström Macroglobulinemia Foundation was secured to create the Waldenström Macroglobulinemia Clinical Trial Network. Additional funding was secured from the Bell Family to create a research fellowship position to focus on translational, transformative basic research at the Bing Center for Waldenström Macroglobulinemia laboratory. He has authored over 300 peer-reviewed articles. Highlights include the results of a prospective study on venetoclax in patients with previously treated Waldenström Macroglobulinemia, the long-term report on ibrutinib in previously untreated Waldenström Macroglobulinemia, and the initial report of a prospective study investigating ibrutinib in previously untreated Waldenström Macroglobulinemia published in the Journal of Clinical Oncology,…

Phone: 617-632-6285Email: This email address is being protected from spambots. You need JavaScript enabled to view it. Chris Patterson is the Administrative Director of the Bing Center for Waldenstrom’s Macroglobulinemia. After completing his undergraduate studies at Kings College, and the University of Heidelberg in Germany, Chris studied immunology and biochemistry at the Harvard University Extension School, Cambridge MA. In 2005, Chris joined the Bing Center as a Clinical Research Coordinator and was responsible for clinical trials examining the role of sildenafil, imatinib mesylate, and bortezomib in the treatment of Waldenstrom’s Macroglobulinemia. In 2007, he undertook the role of Administrative Director for the Bing Center, and led the expansion of the Bing Center Basic Science and Clinical Trial Efforts. In 2008, Chris served as the Secretariat of the highly successful 5th International Workshop on Waldenstrom’s Macroglobulinemia which took place in Stockholm, Sweden and attracted senior and young investigators from around the world for a 4 day scientific workshop on WM. For his efforts, Chris was honored at the closing ceremonies, which took part in the Nobel Hall. In 2009, Chris organized the 3rd International Summit on WM, which brought over 600 patients and physicians to Boston for a 3-day Summit on WM. In addition to his administrative roles, Chris has been a strong advocate for WM patient education, and is also the coordinator for the New England WM Support Group. He has organized numerous regional WM support group meetings throughout North America and Europe, including the 2009 Toronto Summit on WM. Among his research interests, Chris undertook studies addressing cholesterol and iron deficiency in WM,…